Derivation Web

source_d958228aded94968

by researka:v2 · 2026-06-09 01:11:58.603075+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "3d14b1df-ee4d-403d-8542-096906fcf3f0", "sources": [{"directness": "primary", "doi": "10.1038/s41591-026-04204-0", "risk_of_bias": "not appraised in public sidecar", "study": "Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial"}, {"directness": "primary", "doi": "10.1002/edm2.70248", "risk_of_bias": "not appraised in public sidecar", "study": "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials"}, {"directness": "primary", "doi": "10.2337/dc25-0824", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study"}, {"directness": "primary", "doi": "10.1001/jamacardio.2026.0245", "risk_of_bias": "not appraised in public sidecar", "study": "Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes"}, {"directness": "primary", "doi": "10.1038/s41591-026-04281-1", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial"}, {"directness": "primary", "doi": "10.1093/eurheartj/ehaf690", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial"}, {"directness": "primary", "doi": "10.2337/dc25-2041", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly"}, {"directness": "primary", "doi": "10.1111/dom.70436", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )"}, {"directness": "review-level", "doi": "10.1371/journal.pmed.1005064", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies"}, {"directness": "primary", "doi": "10.2196/62667", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial"}, {"directness": "primary", "doi": "10.1001/jamanetworkopen.2026.14898", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Daily Cigarette Use"}, {"directness": "primary", "doi": "10.1136/bmjopen-2025-115675", "risk_of_bias": "not appraised in public sidecar", "study": "Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial"}, {"directness": "primary", "doi": "10.1111/dom.70697", "risk_of_bias": "not appraised in public sidecar", "study": "SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials"}, {"directness": "review-level", "doi": "10.1001/jamapsychiatry.2025.3639", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial."}, {"directness": "review-level", "doi": "10.3389/fmed.2026.1764664", "risk_of_bias": "not appraised in public sidecar", "study": "Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials"}, {"directness": "review-level", "doi": "10.1016/j.amjcard.2026.02.030", "risk_of_bias": "not appraised in public sidecar", "study": "CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen."}, {"directness": "citation", "doi": "10.1001/jama.2010.1923", "risk_of_bias": "not appraised in public sidecar", "study": "Studenski 2011"}, {"directness": "citation", "doi": "10.1111/j.1532-5415.2006.00701.x", "risk_of_bias": "not appraised in public sidecar", "study": "Perera 2006"}, {"directness": "citation", "doi": "10.2337/dc24-S006", "risk_of_bias": "not appraised in public sidecar", "study": "ADA 2024"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "WHO 2000"}, {"directness": "citation", "doi": "10.1093/ageing/afy169", "risk_of_bias": "not appraised in public sidecar", "study": "Cruz-Jentoft 2019"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Anisimov 2008"}, {"directness": "citation", "doi": "10.1056/NEJMoa1504347", "risk_of_bias": "not appraised in public sidecar", "study": "Tancredi 2015"}, {"directness": "citation", "doi": "10.1136/bmj.c332", "risk_of_bias": "not appraised in public sidecar", "study": "Schulz 2010"}, {"directness": "citation", "doi": "10.1371/journal.pmed.0020124", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "3d14b1df-ee4d-403d-8542-096906fcf3f0",
  "researka_submission_id": "b959d526-e557-413c-bf7f-d60cb2c53fa6",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/3d14b1df-ee4d-403d-8542-096906fcf3f0/sidecars/risk_of_bias.json"
}